Ginkgo Bioworks Holdings, Inc. (DNA)
After hours:
| Previous Close | 1.9600 |
| Open | 1.9400 |
| Bid | 2.0100 x 36900 |
| Ask | 2.0100 x 28000 |
| Day's Range | 1.9000 - 2.0200 |
| 52 Week Range | 1.4500 - 6.3000 |
| Volume | |
| Avg. Volume | 23,348,111 |
| Market Cap | 4.107B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6720 |
| Earnings Date | Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.92 |
- GlobeNewswire
Ginkgo Bioworks and XpresCheck Expand CDC’s Traveler-Based Genomic Surveillance Program to Detect Influenza Variants
The program is an effective early warning system for viral variants, leveraging voluntary sampling from international travelers at major U.S. airportsBOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA) and XWELL, Inc. (Nasdaq: XWEL) today announced that they have expanded their support for the Centers for Disease Control and Prevention’s (CDC’s) Traveler-based Genomic Surveillance program to include a pilot study monitoring influenza viruses in addition to SARS-CoV
- GlobeNewswire
Ginkgo Bioworks and XpresCheck Receive Award to Expand CDC’s Traveler-Based SARS-CoV-2 Genomic Surveillance Program In U.S. Airports
Public-private partnership to enable the development of innovative, sustainable infrastructure designed to set the global standard for travel biosecurityBOSTON and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA) and XpresSpa Group, Inc. (Nasdaq: XSPA) announced they will continue to support the Centers for Disease Control and Prevention’s (CDC’s) traveler-based SARS-CoV-2 genomic surveillance program through a new contract awarded August 12, 2022. The partnership is expec
- Yahoo Finance Video
Ginkgo Bioworks partners with Synlogic on new gout drug
Ginkgo is teaming up with Synlogic to launch a new gout drug, moving shares of both stocks higher.
